Vanguard Portfolio Management
CRL icon

Vanguard Portfolio Management’s Charles River Laboratories CRL Stock Holding History

Vanguard Portfolio Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$501M Sell
2,210,979
-83,691
-4% -$14.9M 0.02% 709
2026
Q1 		$396M Buy
+2,294,670
New +$425M 0.02% 756

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management's CRL Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its Charles River Laboratories (CRL) stake by 3.6% in Q2 2026, selling an estimated $14.9M and leaving 2,210,979 shares worth $501M. The position accounts for 0.02% of the portfolio, ranked #709.

Vanguard Portfolio Management first reported a position in CRL in Q1 2026 and has held it in 2 quarters since. 531 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Vanguard Portfolio Management held 2,210,979 shares of Charles River Laboratories worth $501M as of Q2 2026.
  • Vanguard Portfolio Management sold 83,691 Charles River Laboratories shares in Q2 2026, an estimated $14.9M.
  • Charles River Laboratories made up 0.02% of Vanguard Portfolio Management's portfolio in Q2 2026, its #709 holding.
  • Vanguard Portfolio Management first reported a position in Charles River Laboratories in Q1 2026 and has held it in 2 quarters since.
  • 531 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.